Charles R. Schwab, Co-Chairman of Charles Schwab Corp. (NASDAQ:SCHW), executed a sale of common stock on May 19, 2026. Specifically, Mr. Schwab sold 27,500 shares of the company's equity. The transaction involved varied selling prices, which ranged between $91.95 and $92.54 per share. Utilizing a weighted average calculation, the sale generated an average price of $92.2228 per share. Overall, this divestment totaled $2,536,127.
It is noted that at the time of the reported transaction, the stock was trading at $90.11, which positioned it near its 52-week low and beneath the fair value assessment provided by InvestingPro. This context suggests that, based on valuation metrics, the shares might be considered undervalued.
The company currently reports a market capitalization of $156.35 billion and maintains a Price/Earnings (P/E) ratio of 17.94. The sale itself was managed indirectly through a Limited Partnership structure. Following this specific transaction, the Limited Partnership holds an indirect stake amounting to 30,209,768 shares of Charles Schwab common stock.
Beyond this recent divestment, Mr. Schwab retains other substantial indirect holdings in the corporation. These include 54,384,341 shares held by a Trust, 44,025 shares managed by 188 Corp, and an additional 10,624,797.33 shares held through a Spouse as Trustee.
Despite the reported sale activity, Charles Schwab has been the subject of considerable attention from various analyst firms in the wake of its 2026 Investor Day. These subsequent reports indicate a broadly positive consensus regarding the company’s future performance and operational trajectory.
Major financial institutions issued several updates following the event. TD Cowen raised its price target for Charles Schwab to $109, while maintaining an 'Buy' rating. This firm also adjusted its estimates for earnings per share for both 2026 and 2027. Similarly, Piper Sandler increased its own price target to $105. Their rationale included citing improved revenue guidance, which is expected to be driven by net interest margin growth toward the end of the year. However, Piper Sandler maintained a 'Neutral' rating.
Citizens reaffirmed its 'Market Outperform' rating and set a price target of $120, expressing confidence in the company’s expanding proprietary growth algorithm. Barclays elevated its price target to $127 while keeping an 'Overweight' rating. In their analysis, Barclays specifically noted that management does not perceive any threat from plans to introduce AI-powered cash optimization tools by Charles Schwab.
Furthermore, Raymond James also raised its price target significantly to $137, maintaining an 'Outperform' rating for the stock. These multiple updates collectively reflect a strong and positive outlook provided by analysts concerning Charles Schwab’s anticipated future performance.
Risks
- <li style="margin-bottom: 10px;"><strong>Executive Selling Activity:</strong> The direct sale of shares by Co-Chairman Charles R. Schwab, while not definitive, adds a layer of scrutiny to the stock's valuation and internal confidence perception.</li>
- <li style="margin-bottom: 10px;"><strong>Market Timing vs. Analyst Forecast:</strong> There is a divergence between the current market price (near 52-week low) and the significantly higher price targets set by various analysts, creating potential uncertainty regarding the immediate path to achieving these projected valuations.</li>
- <li style="margin-bottom: 10px;"><strong>Dependence on External Growth Factors:</strong> The positive outlook is heavily tied to expected net interest margin growth and the success of the company's expanding proprietary growth algorithm, making performance vulnerable to shifts in interest rate environments or market conditions affecting these key revenue streams.</li>
More from Insider Trading
Risks
- <li style="margin-bottom: 10px;"><strong>Executive Selling Activity:</strong> The direct sale of shares by Co-Chairman Charles R. Schwab, while not definitive, adds a layer of scrutiny to the stock's valuation and internal confidence perception.</li>
- <li style="margin-bottom: 10px;"><strong>Market Timing vs. Analyst Forecast:</strong> There is a divergence between the current market price (near 52-week low) and the significantly higher price targets set by various analysts, creating potential uncertainty regarding the immediate path to achieving these projected valuations.</li>
- <li style="margin-bottom: 10px;"><strong>Dependence on External Growth Factors:</strong> The positive outlook is heavily tied to expected net interest margin growth and the success of the company's expanding proprietary growth algorithm, making performance vulnerable to shifts in interest rate environments or market conditions affecting these key revenue streams.</li>